医学
间质性肺病
观察研究
临床试验
精密医学
肺病
重症监护医学
疾病
呼吸道疾病
队列研究
个性化医疗
免疫学
梅德林
内科学
肺功能
病理
鉴别诊断
肺
队列
急性药物
重症监护室
疾病严重程度
内型
回顾性队列研究
重症监护
作者
Manoj V. Maddali,Janelle Vu Pugashetti,Shaun M. Pienkos,Andrew Reese Moore,Samuel Konkol,John S. Kim,Shwu-Fan Ma,Chad A. Newton,Christine Kim Garcia,Ayodeji Adegunsoye,Mary E. Strek,Ching‐Hsien Chen,A. Linderholm,Rachel L. Zemans,Bethany B. Moore,Paul J. Wolters,R. Raj,Jonathan H. Chen,Fernando J. Martínez,Imre Noth
标识
DOI:10.1093/ajrccm/aamag006
摘要
RATIONALE: Interstitial lung diseases (ILDs) are a clinically and biologically diverse group of disorders characterized by varying inflammation and fibrosis of the lung parenchyma. Immunosuppressant therapy is commonly used to treat non-idiopathic pulmonary fibrosis (non-IPF) ILD, but treatment response is variable and difficult to predict. OBJECTIVE: Identify and validate molecular endotypes of non-IPF ILD. METHODS: Twenty plasma proteins associated with inflammation were used to perform latent class analysis in 2 observational non-IPF ILD cohorts (discovery n = 676; validation n = 585). Proteins were measured using a semi-quantitative Olink Explore 3072 platform. The primary outcome was 3-year transplant-free survival. Weighted Cox regression was used to assess differential response to mycophenolate or azathioprine in each cohort according to molecular endotype classification. RESULTS: A 2-class model best fit both cohorts (P <0.01), with Class 2 comprising ∼30% of patients. Compared to Class 1, Class 2 was associated with significantly lower 3-year transplant-free survival in both discovery (78% vs 36%, P <0.001) and validation (83% vs 46%, P <0.001) cohorts. Significant interaction between molecular endotype and immunosuppressant exposure was observed in both cohorts (discovery Pinteraction = 0.022; validation Pinteraction = 0.019), with survival benefit seen only in Class 2. In pooled analysis, similar trends were observed irrespective of ILD subtype. Pathway analysis supported enrichment of inflammatory signatures in Class 2. CONCLUSION: In this multicenter observational cohort study, we identified and validated 2 distinct molecular endotypes of non-IPF ILD with divergent outcomes and response to immunosuppressant therapy. These endotypes could inform precision medicine strategies and clinical trial design in ILD.
科研通智能强力驱动
Strongly Powered by AbleSci AI